Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.

Bilello JP, Lallos LB, McCarville JF, La Colla M, Serra I, Chapron C, Gillum JM, Pierra C, Standring DN, Seifer M.

Antimicrob Agents Chemother. 2014 Aug;58(8):4431-42. doi: 10.1128/AAC.02777-13. Epub 2014 May 27.

2.

Evaluation of the role of three candidate human kinases in the conversion of the hepatitis C virus inhibitor 2'-C-methyl-cytidine to its 5'-monophosphate metabolite.

Golitsina NL, Danehy FT Jr, Fellows R, Cretton-Scott E, Standring DN.

Antiviral Res. 2010 Mar;85(3):470-81. doi: 10.1016/j.antiviral.2009.10.020. Epub 2009 Oct 31.

PMID:
19883694
3.

Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.

Seifer M, Patty A, Serra I, Li B, Standring DN.

Antiviral Res. 2009 Feb;81(2):147-55. doi: 10.1016/j.antiviral.2008.10.008. Epub 2008 Nov 24.

PMID:
19028525
4.

Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

Pierra C, Amador A, Benzaria S, Cretton-Scott E, D'Amours M, Mao J, Mathieu S, Moussa A, Bridges EG, Standring DN, Sommadossi JP, Storer R, Gosselin G.

J Med Chem. 2006 Nov 2;49(22):6614-20.

PMID:
17064080
5.

Antiviral beta-L-nucleosides specific for hepatitis B virus infection.

Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach JL, Hernandez B, Juodawlkis A, Tennant B, Korba B, Cote P, Cretton-Scott E, Schinazi RF, Myers M, Bryant ML, Sommadossi JP.

Antivir Chem Chemother. 2001;12 Suppl 1:119-29.

PMID:
11594678
6.

Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3.

Butkiewicz N, Yao N, Zhong W, Wright-Minogue J, Ingravallo P, Zhang R, Durkin J, Standring DN, Baroudy BM, Sangar DV, Lemon SM, Lau JY, Hong Z.

J Virol. 2000 May;74(9):4291-301.

7.

Development of novel anti-HCV therapies: HCV protease, helicase, and polymerase as therapeutic targets.

Hong Z, Standring DN, Baroudy B, Lau JY.

Acta Gastroenterol Belg. 2000 Apr-Jun;63(2):210-2. Review. No abstract available.

PMID:
10925468
8.

Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.

Genovesi EV, Lamb L, Medina I, Taylor D, Seifer M, Innaimo S, Colonno RJ, Standring DN, Clark JM.

Antimicrob Agents Chemother. 1998 Dec;42(12):3209-17. Erratum in: Antimicrob Agents Chemother 1999 Mar;43(3):726.

9.

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

Seifer M, Hamatake RK, Colonno RJ, Standring DN.

Antimicrob Agents Chemother. 1998 Dec;42(12):3200-8.

10.

Generation of replication-competent hepatitis B virus nucleocapsids in insect cells.

Seifer M, Hamatake R, Bifano M, Standring DN.

J Virol. 1998 Apr;72(4):2765-76.

11.

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus.

Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ.

Antimicrob Agents Chemother. 1997 Jul;41(7):1444-8.

12.

Ribonucleoprotein complex formation by the human hepatitis B virus polymerase.

Seifer M, Standring DN.

Intervirology. 1995;38(5):295-303.

PMID:
8724861
13.

Assembly and antigenicity of hepatitis B virus core particles.

Seifer M, Standring DN.

Intervirology. 1995;38(1-2):47-62. Review.

PMID:
8666524
15.
19.

Hepatitis B virus capsid particles are assembled from core-protein dimer precursors.

Zhou S, Standring DN.

Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10046-50.

21.
22.

Characterization of hepatitis B virus capsid particle assembly in Xenopus oocytes.

Zhou S, Yang SQ, Standring DN.

J Virol. 1992 May;66(5):3086-92.

25.
26.

Insulin-like growth factor II receptor as a multifunctional binding protein.

Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, Roth RA, Rutter WJ.

Nature. 1987 Sep 24-30;329(6137):301-7.

PMID:
2957598
27.
28.

The molecular analysis of hepatitis B virus.

Standring DN, Rutter WJ.

Prog Liver Dis. 1986;8:311-33. Review. No abstract available.

PMID:
3012638
29.
30.

Hepatitis B virus encodes an RNA polymerase III transcript.

Standring DN, Rall LB, Laub O, Rutter WJ.

Mol Cell Biol. 1983 Oct;3(10):1774-82.

31.

Transcription of hepatitis B virus by RNA polymerase II.

Rall LB, Standring DN, Laub O, Rutter WJ.

Mol Cell Biol. 1983 Oct;3(10):1766-73.

32.

Synthesis of hepatitis B surface antigen in mammalian cells: expression of the entire gene and the coding region.

Laub O, Rall LB, Truett M, Shaul Y, Standring DN, Valenzuela P, Rutter WJ.

J Virol. 1983 Oct;48(1):271-80.

33.

Rat preprocarboxypeptidase A: cDNA sequence and preliminary characterization of the gene.

Quinto C, Quiroga M, Swain WF, Nikovits WC Jr, Standring DN, Pictet RL, Valenzuela P, Rutter WJ.

Proc Natl Acad Sci U S A. 1982 Jan;79(1):31-5.

34.

Yeast tRNA3Leu gene transcribed and spliced in a HeLa cell extract.

Standring DN, Venegas A, Rutter WJ.

Proc Natl Acad Sci U S A. 1981 Oct;78(10):5963-7.

36.

Reduction of aryl azides by thiols: implications for the use of photoaffinity reagents.

Staros JV, Bayley H, Standring DN, Knowles JR.

Biochem Biophys Res Commun. 1978 Feb 14;80(3):568-72. No abstract available.

PMID:
24446
37.

Supplemental Content

Loading ...
Support Center